Tế bào miễn dịch tăng lên trong mô vú bình thường của người mang đột biến BRCA1/2

Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822 Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25(43):5864–5874 Venkitaraman AR (2001) Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 114(Pt 20):3591–3598 Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF et al (2016) Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7(12):13587–13598 Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L et al (2016) RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 22(8):933–939 He Z, Ghorayeb R, Tan S, Chen K, Lorentzian AC, Bottyan J et al (2022) Pathogenic BRCA1 variants disrupt PLK1-regulation of mitotic spindle orientation. Nat Commun 13(1):2200 He Z, Kannan N, Nemirovsky O, Chen H, Connell M, Taylor B et al (2017) BRCA1 controls the cell division axis and governs ploidy and phenotype in human mammary cells. Oncotarget 8(20):32461–32475 Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP et al (2017) Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aal4922 Ren Y, Cherukuri Y, Wickland DP, Sarangi V, Tian S, Carter JM et al (2020) HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. Oncoimmunology 9(1):1744947 Brandtzaeg P (2010) The mucosal immune system and its integration with the mammary glands. J Pediatr 156(2 Suppl):S8-15 Goldman AS (1993) The immune system of human milk: antimicrobial, antiinflammatory and immunomodulating properties. Pediatr Infect Dis J 12(8):664–671 Spencer JP (2008) Management of mastitis in breastfeeding women. Am Fam Phys 78(6):727–731 Zumwalde NA, Haag JD, Sharma D, Mirrielees JA, Wilke LG, Gould MN et al (2016) Analysis of immune cells from human mammary ductal epithelial organoids reveals Vδ2+ T cells that efficiently target breast carcinoma cells in the presence of bisphosphonate. Cancer Prev Res (Phila) 9(4):305–316 Hebbard L, Steffen A, Zawadzki V, Fieber C, Howells N, Moll J et al (2000) CD44 expression and regulation during mammary gland development and function. J Cell Sci 113(Pt 14):2619–2630 Gillespie SL, Porter K, Christian LM (2016) Adaptation of the inflammatory immune response across pregnancy and postpartum in Black and White women. J Reprod Immunol 114:27–31 O’Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L et al (2010) Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol 176(3):1241–1255 Schedin P, O’Brien J, Rudolph M, Stein T, Borges V (2007) Microenvironment of the involuting mammary gland mediates mammary cancer progression. J Mammary Gland Biol Neoplasia 12(1):71–82 McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W et al (2006) Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 168(2):608–620 Lyons TR, O’Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW et al (2011) Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 17(9):1109–1115 Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD et al (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98(22):1600–1607 Degnim AC, Brahmbhatt RD, Radisky DC, Hoskin TL, Stallings-Mann M, Laudenschlager M et al (2014) Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Res Treat 144(3):539–549 Degnim AC, Hoskin TL, Arshad M, Frost MH, Winham SJ, Brahmbhatt RA et al (2017) Alterations in the immune cell composition in premalignant breast tissue that precede breast cancer development. Clin Cancer Res 23(14):3945–3952 Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K et al (2005) Benign breast disease and the risk of breast cancer. New Engl J Med 353(3):229–237 Sherman ME, Figueroa JD, Henry JE, Clare SE, Rufenbarger C, Storniolo AM (2012) The Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center: a unique resource for defining the “molecular histology” of the breast. Cancer Prev Res (Phila) 5(4):528–535 Radisky DC, Santisteban M, Berman HK, Gauthier ML, Frost MH, Reynolds CA et al (2011) p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) 4(12):1953–1960 Zirbes A, Joseph J, Lopez JC, Sayaman RW, Basam M, Seewaldt VL et al (2021) Changes in immune cell types with age in breast are consistent with a decline in immune surveillance and incresaed immunosuppression. J Mammary Gland Biol Neoplasia 26(3):247–261 Heinze G, Puhr R (2010) Bias-reduced and separation-proof conditional logistic regression with small or sparse data sets. Stat Med 29(7–8):770–777 Hermsen BB, von Mensdorff-Pouilly S, Fabry HF, Winters HA, Kenemans P, Verheijen RH et al (2005) Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer. J Pathol 206(2):220–223 Gulbahce HE, Vanderwerf S, Blair C, Sweeney C (2014) Lobulitis in nonneoplastic breast tissue from breast cancer patients: association with phenotypes that are common in hereditary breast cancer. Hum Pathol 45(1):78–84 Hussein MR, Hassan HI (2006) Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol 59(9):972–977 Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM (2012) Leukocyte composition of human breast cancer. Proc Natl Acad Sci USA 109(8):2796–2801 Wen WX, Leong CO (2019) Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS ONE 14(4):e0215381 Castle JC, Uduman M, Pabla S, Stein RB, Buell JS (2019) Mutation-derived neoantigens for cancer immunotherapy. Front Immunol 10:1856 Luen S, Virassamy B, Savas P, Salgado R, Loi S (2016) The genomic landscape of breast cancer and its interaction with host immunity. Breast (Edin) 29:241–250 Kato T, Park JH, Kiyotani K, Ikeda Y, Miyoshi Y, Nakamura Y (2017) Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. Oncotarget 8(37):62029–62038 Morand S, Stanbery L, Walter A, Rocconi RP, Nemunaitis J (2020) BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target. JNCI Cancer Spectr 4(6):pkaa077 Reisländer T, Lombardi EP, Groelly FJ, Miar A, Porru M, Di Vito S et al (2019) BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors. Nat Commun 10(1):3143 Oishi Y, Manabe I (2018) Macrophages in inflammation, repair and regeneration. Int Immunol 30(11):511–528 Hamidzadeh K, Christensen SM, Dalby E, Chandrasekaran P, Mosser DM (2017) Macrophages and the recovery from acute and chronic inflammation. Annu Rev Physiol 79:567–592 Locati M, Curtale G, Mantovani A (2020) Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol 15:123–147 Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S et al (2018) Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell 174(5):1293-1308.e36